Product Spotlight: Fluorescent Endocannabinoids
April 12, 2016
Avanti’s new Fluorescent Endocannabinoids may be used to map the impact of various treatments and inhibitors on endocannabinoid uptake and distribution in living cells.
The endocannabinoid pathway influences behavior, lipogenesis, embryologic development, and pathophysiological effects including pain, inflammation, stress, obesity, and non-alcoholic fatty liver disease. Endogenous endocannabinoids including arachidonoylethanolamide (anandamide, AEA) and 2-arachidonoylglycerol (2-AG) are derived from arachidonic acid (AA). Fluorescent NBD-AA, NBD-AEA, and NBD-2-AG analogues are direct probes that can be used for visualizing the uptake, intracellular trafficking, and targeting of these molecules by living cells, as well as measuring the binding of endocannabinoids to cytosolic binding proteins. Importantly, direct binding studies show the affinities of the fluorescent analogues are in the same range as the respective unlabeled ligands. Fluorescent endocannabinoid probes are useful for mapping the impact of various treatments, inhibitors, etc on endocannabinoid uptake and distribution in living cells.